ERBB2 and breast carcinoma: The results showed that the expression levels of SIRT7 were correlated with most markers of different immune cells in breast cancer subtypes (breast cancer-luminal, n = 611; breast cancer-basal, n = 139; breast cancer-HER2+, n = 67).